THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

GLIOMATCH selected for Horizon Europe funding

The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.

GLIOMATCH is now a Horizon Europe funded Research and Innovation Action. The project is aimed at improving the outcome of malignant brain tumours in adults and children, as well as better understanding immunotherapy for brain cancer treatment.

By investigating solutions to alleviate the societal impacts of brain cancer, the project aligns with the objectives of the EU Cancer Mission and contributes to the United Nations’ Sustainable Development Goals 2 and 4.

It is a five year project starting in January 2024 and aligning 14 pan-European partners from 10 different member states.

More Posts

GLIOMATCH marks World Brain Tumour Day at EU event on advancing brain cancer research

On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.

GLIOMATCH: Explained with Prof. Dr. Steven De Vleeschouwer

In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.

GLIOMATCH 5th consortium meeting takes place in Barcelona

On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).